Skip to main content
    A

    Avadel Pharmaceuticals PLC (AVDL)

    Official site

    DRUG MANUFACTURERS - SPECIALTY & GENERIC

    $21.64
    +0.00 (+0.00%)

    Last updated: Feb 12, 2026 at 4:00 PM ET

    Avadel Pharmaceuticals PLC (AVDL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2025. Financial statements from company filings, amounts in US dollars.

    Avadel Pharmaceuticals reported revenue of $169.12M for the fiscal year ended Dec 31, 2024, up 504.8% from the year before. That year, net income was -$48.83M with a net margin of -28.9%, operating cash flow was -$46.91M and free cash flow was -$46.91M. The quarter ended Sep 30, 2025 had revenue of $77.47M and net income of $20.00K.

    Revenue and Margins

    The operating margin was -25.1% in the fiscal year ended Dec 2024. Over the 9 years to Dec 2024, revenue fell from $173.21M, a compound annual decline of 0.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$169.12M+504.8%91.0%-25.1%-28.9%
    Dec 2023$27.96MN/A97.0%-493.0%-573.2%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$22.33M-62.3%74.3%26.0%31.5%
    Dec 2019$59.22M-42.7%79.5%-40.7%-56.1%
    Dec 2018$103.27M-40.2%83.0%-101.6%-92.3%
    Dec 2017$172.74M+15.0%90.6%51.1%38.9%
    Dec 2016$150.25M-13.3%91.2%-3.3%-27.5%
    Dec 2015$173.21MN/A93.7%41.2%23.5%
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$169.12M$27.96M$0$0$22.33M$59.22M$103.27M$172.74M$150.25M$173.21M
    Cost of revenue$15.28M$846.00K$0$0$5.74M$12.13M$17.52M$16.30M$13.25M$10.92M
    Gross profit$153.84M$27.12M$0$0$16.59M$47.09M$85.75M$156.44M$137.00M$162.29M
    Research and development$15.20M$13.26M$20.70M$17.10M$20.44M$32.92M$39.33M$34.22M$34.61M$25.61M
    Operating income-$42.40M-$137.85M-$98.56M-$85.55M$5.82M-$24.11M-$104.93M$88.30M-$4.96M$71.45M
    Net income-$48.83M-$160.28M-$137.46M-$77.33M$7.03M-$33.23M-$95.30M$67.25M-$41.28M$40.66M
    EBITDA-$35.57MN/A-$97.60M-$82.39M$9.60M-$23.61M-$95.14MN/A$5.73M$115.54M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$77.47M$68.13M$52.51M$50.41M$50.02M$41.50M$27.18M$19.45M$7.01M$1.50M$0$0
    Gross profit$80.47M$61.76M$46.93M$45.60M$43.87M$38.72M$25.66M$18.76M$6.90M$1.46M$0-$586.00K
    Operating income$1.94M$8.88M-$3.00M-$3.30M-$327.00K-$12.74M-$26.04M-$24.90M-$35.11M-$49.54M-$28.30M-$23.22M
    Net income$20.00K$9.66M-$4.92M-$5.04M-$2.63M-$13.82M-$27.34M-$28.79M-$36.27M-$64.43M-$30.78M-$27.45M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, the balance sheet showed $51.37M in cash and equivalents and no debt.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$164.24M$164.70M$132.78M$247.26M$311.64M$151.44M$190.30M$252.11M$245.48M$214.98M
    Current assets$134.21M$134.20M$100.84M$192.49M$263.45M$82.38M$124.85M$123.95M$181.19M$166.31M
    Cash and equivalents$51.37M$31.17M$73.98M$50.71M$71.72M$9.77M$9.32M$16.56M$39.22M$65.06M
    Total liabilities$90.39M$76.96M$153.93M$169.02M$149.37M$180.63M$187.52M$167.54M$203.41M$147.11M
    Short-term debt$0$0$37.67M$0$474.00K$645.00K$106.00K$111.00K$268.00K$434.00K
    Long-term debt$0$0$91.61M$142.40M$128.21M$121.69M$115.73M$156.00K$547.00K$684.00K
    Shareholder equity$73.85M$87.74M-$21.14M$78.24M$162.27M-$29.20M$2.78M$84.56M$42.07M$67.86M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$199.45M$187.16M$167.95M$164.24M$158.25M$157.52M$167.90M$164.70M$203.10M$200.98M$140.74M$204.13M
    Total liabilities$101.22M$96.45M$93.88M$90.39M$83.59M$87.23M$89.52M$76.96M$92.95M$57.78M$178.91M$225.27M
    Cash and equivalents$79.81M$63.40M$56.37M$51.37M$28.58M$28.85M$35.79M$31.17M$51.81M$49.98M$83.39M$73.98M
    Shareholder equity$98.22M$90.71M$74.07M$73.85M$74.66M$70.29M$78.38M$87.74M$110.15M$143.19M-$38.17M-$21.14M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$46.91M-$128.51M-$70.30M-$77.31M-$48.73M-$38.33M-$82.72M$16.66M$18.90M$84.29M
    Capital expenditures$0$0$716.00K$26.00K$98.00K$29.00K$20.18M$53.70M$1.20M$1.63M
    Free cash flow-$46.91M-$128.51M-$71.02M-$77.34M-$48.83M-$38.35M-$102.89M-$37.04M$17.70M$82.66M
    Share repurchases$0$0$0$0$0$0$27.64M$22.36M$0$0
    Investing cash flow$51.78M-$50.09M$79.70M$56.93M-$69.72M$38.72M-$36.98M-$15.70M-$36.63M-$31.73M
    Financing cash flow$15.97M$135.34M$14.54M$263.00K$179.68M-$27.00K$112.66M-$23.32M-$7.95M-$23.75M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow$23.26M$12.70M-$8.23M$7.87M-$6.89M-$18.19M-$29.70M-$28.03M-$38.23M-$32.02M-$30.23M-$15.37M
    Capital expenditures$10.76K$181.00K$0$0$0$0$0$0$0$0$0$716.00K
    Free cash flow$23.25M$12.52M-$8.23M$7.87M-$6.89M-$18.19M-$29.70M-$28.03M-$38.23M-$32.02M-$30.23M-$16.08M
    Last 12 quarters

    Frequently Asked Questions About AVDL

    What is Avadel Pharmaceuticals' annual revenue?

    Avadel Pharmaceuticals reported revenue of $169.12M for the fiscal year ended Dec 31, 2024.

    How fast is Avadel Pharmaceuticals' revenue growing?

    Revenue was up 504.8% for the fiscal year ended Dec 31, 2024 compared with the year before.

    Is Avadel Pharmaceuticals profitable?

    No. Avadel Pharmaceuticals reported net income of -$48.83M for the fiscal year ended Dec 31, 2024, with a net margin of -28.9%.

    How much free cash flow does AVDL generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$46.91M minus capital expenditures of $0 produced free cash flow of -$46.91M.

    How much debt does Avadel Pharmaceuticals have?

    The balance sheet dated Dec 31, 2024 reported long-term debt of $0, short-term debt of $0 and cash and equivalents of $51.37M.